MF
Showing 26 - 50 of 5,757
Asthma Trial (MF/F Metered Dose Inhaler (MDI) 25/5 mcg, MF/F MDI 50/5 mcg, MF/F MDI 100/5 mcg)
Withdrawn
- Asthma
- MF/F Metered Dose Inhaler (MDI) 25/5 mcg
- +6 more
- (no location specified)
Feb 7, 2022
Myelofibrosis, Chronic Myelomonocytic Leukemia Trial in Canada, United States (SL-401)
Active, not recruiting
- Myelofibrosis
- Chronic Myelomonocytic Leukemia
-
Duarte, California
- +9 more
Jan 24, 2023
Asthma Trial (MF)
Completed
- Asthma
- MF
- (no location specified)
Feb 1, 2022
COPD (COPD) Trial (Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI)
Completed
- Chronic Obstructive Pulmonary Disease (COPD)
- Mometasone furoate/formoterol (MF/F) combination
- +3 more
- (no location specified)
Feb 7, 2022
Asthma, COPD Trial (SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F ))
Completed
- Asthma
- COPD
- SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )
- (no location specified)
Feb 7, 2022
Lifetech MFO Post-Market Clinical Follow-Up Study
Recruiting
- Ventricular Septal Defect
- KONAR-MF™ VSD Occluder
-
Bad Oeynhausen, Germany
- +3 more
Nov 24, 2021
Sezary Syndrome, Mycosis Fungoides Trial in Stanford (Mogamulizumab, LD TSEBT)
Recruiting
- Sezary Syndrome
- Mycosis Fungoides
- Mogamulizumab
- LD TSEBT
-
Stanford, CaliforniaStanford Cancer Center
Oct 19, 2022
Influenza (Healthy Volunteers) Trial in United States (Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose
Recruiting
- Influenza (Healthy Volunteers)
- Panblok + MF59 Dose 1
- +2 more
-
Mesa, Arizona
- +15 more
Nov 9, 2022
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis Trial in Houston
Completed
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
May 27, 2022
HIV Trial in Rochester (MTP-PE/MF59, Env 2-3)
Completed
- HIV Infections
- MTP-PE/MF59
- Env 2-3
-
Rochester, New YorkUniv. of Rochester AVEG
Oct 27, 2021
Anorexia Nervosa Trial in Palo Alto (Multi-Family Guided Self-Help FBT)
Recruiting
- Anorexia Nervosa
- Multi-Family Guided Self-Help FBT
-
Palo Alto, CaliforniaStanford University
Jun 30, 2022
HIV, HIV Seronegativity Trial in Rochester, Nashville, Seattle (MTP-PE/MF59, Env 2-3)
Completed
- HIV Infections
- HIV Seronegativity
- MTP-PE/MF59
- Env 2-3
-
Rochester, New York
- +2 more
Oct 28, 2021
SARS-CoV-2 Trial in Melbourne (Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59),
Recruiting
- SARS-CoV-2
- Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59)
- +2 more
-
Melbourne, Victoria, Australia
- +1 more
Apr 25, 2022
Influenza, Human Trial (Investigational aQIVc, licensed QIV1, licensed QIV2)
Not yet recruiting
- Influenza, Human
- Investigational aQIVc
- +2 more
- (no location specified)
Aug 28, 2023
Characterize Patients Initiating Enerzair® Breezhaler®, With or
Withdrawn
- Asthma
- IND/GLY/MF
- (no location specified)
Mar 22, 2022
Mycosis Fungoides Trial in Leiden (Chlormethine)
Recruiting
- Mycosis Fungoides
-
Leiden, NetherlandsCentre for Human Drug Research
Mar 29, 2022
Cutaneous T Cell Lymphoma, Mycosis Fungoides Trial (Mogamulizumab, Brentuximab vedotin)
Not yet recruiting
- Cutaneous T Cell Lymphoma
- Mycosis Fungoides
- Mogamulizumab
- Brentuximab vedotin
- (no location specified)
Dec 7, 2022
Primary Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis Trial in Worldwide (RO7490677,
Asthma Trial (Mometasone furoate dry powder inhaler, Placebo)
Completed
- Asthma
- Mometasone furoate dry powder inhaler
- Placebo
- (no location specified)
Feb 7, 2022
Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome Trial in Zürich (Methoxsalen, THERAKOS CELLEX Photopheresis
Withdrawn
- Lymphoma, T-Cell, Cutaneous
- Mycosis Fungoides/Sezary Syndrome
- Methoxsalen
- THERAKOS CELLEX Photopheresis System
-
Zürich, SwitzerlandUniversitaetsSpital Zurich - Division of Dermatology
Aug 31, 2021
Cataract Trial in Wenzhou (SN6AD1, SBL-3, LS-313 MF30)
Recruiting
- Cataract
- SN6AD1
- +5 more
-
Wenzhou, Zhejiang, ChinaThe Eye Hispital of Wenzhou Medical University
Oct 4, 2021
Primary Myelofibrosis, Secondary Myelofibrosis, PMF Trial in Germany (INCB018424/CC-4047)
Active, not recruiting
- Primary Myelofibrosis
- +5 more
-
Aachen, Germany
- +16 more
Sep 28, 2021